June 23, 2022 4:34pm

Five (5) positive sessions, 1 holiday out of seven (7) closing sessions; algorithms are lurking

Pre-open indications: 3 HITs

WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions.  Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

It’s a quick read to understand the ebb and flow of the session in one site

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +194.23 points (+0.64%); the S&P closed UP +35.84 points (+0.95%) while the Nasdaq closed UP +179.11 points (+1.62%)

 

Henry’omics:

The Dow, Nasdaq and S&P 500 jumped on Thursday as bond yields slid weighing recession risks

Indexes have been in flux this week so far, as investors watch for signals on monetary policy while trying to spot signs of an economic slowing.

Is Now a Good Time to Buy This Biotech Stock – bluebird bio (BLUE)? <Motley Fool> https://www.fool.com/investing/2022/06/23/is-now-a-good-time-to-buy-this-biotech-stock/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article Is Now a Good 

 

Economic Data Docket: The Labor Department said U.S. weekly jobless claims fell 2,000 to a seasonally adjusted 229,000 for the week ended June 18, though the labor market remains tight. Shortly after the market's open, the S&P Global purchasing managers index for June showed a drop to 51.2 in June from 53.6 in May. It was the weakest increase in five months, while weaker demand led to the first contraction in new orders since July 2020. The flash PMI report also noted that while costs remain high, the rise in input prices was the slowest since April 2021. <IBD>

 

RegMed Investor’s (RMi) Pre-Open: “as share pricing recognition responds, fear still lingers. Again, for how long does take for sustainability to kick-in and last?” … https://www.regmedinvestors.com/articles/12484

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Thursday opened positive at 21 up/ 13 downs and 1 flat, stayed positive at the mid-day to 24/10 and 1 flat, ending with a positive close of 27/7 and 1 flat.

 

Pre-open Indications: 3 HITs < Verve Therapeutics (VERV +$2.08), Caribou Biosciences (CRBU +$0.18), Biostage (BSTG -$0.09 with 107 shares traded);

 

Key Metrics: review the volume disparities between daily sessions …

  • Thursday - Sector volume was HIGHER with 16 of the 32-upside having higher than the 3-month average volume with LOW volume of 2 of 3-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB was up +4.20% and the XBI was up +6.18%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +0.04 points or +0.14% at 28.99

 

Jumping with share pricing momentum (10 of 32):

  • Intellia Therapeutics (NTLA +$5.22 after Wednesday’s +$1.06 and Tuesday’s +$1.50),
  • CRISPR Therapeutics (CRSP +$5.21 after Wednesday’s -$4.73 and Tuesday’s -$5.33),
  • Alnylam Pharmaceuticals (ALNY +$4.74 after Wednesday’s +$2.54 and Tuesday’s +$1.93),
  • uniQure NV (QURE +$4.14 after announcing safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing P1/2 clinical trial of AMT-130 for the treatment of Huntington’s disease.
  • Ultragenyx (RARE +$3.87),
  • Regenxbio (RGNX +$2.58 after Wednesday’s +$1.89 and Tuesday’s +$0.91),
  • Beam Therapeutics (BEAM +$2.44 after Wednesday’s +$1.08 and Tuesday’s +$2.28),
  • Verve Therapeutics (VERV +$2.08 after Wednesday’s +$1.07),
  • Fate Therapeutics (FATE +$2.00 after Wednesday’s +$11.38 and Tuesday’s +$1.19),
  • Ionis Pharmaceuticals (IONS +$1.78 after Wednesday’s -$0.17),

Closing down (3 of 3):

  • bluebird bio (BLUE -$0.18),
  • Biostage (BSTG -$0.09 after Wednesday’s $0.00 and Tuesday’s +$0.09),
  • Mesoblast (MESO -$0.03 after Tuesday’s -$0.01),

 

June, Q2/2022:

  • Thursday closed positive with 32 incliner and 3 decliners
  • Wednesday closed positive with 27 incliner, 7 decliners and 1 flat
  • Tuesday closed positive with 26 incliner, 7 decliners and 2 flats
  • Monday was market holiday

 

The BOTTOM LINE: Another session to be thankful, the cell and gene therapy remained up on Thursday following Wednesday with three (3) positive sessions.

I am looking at the volatility index that is down just slightly, it is not really buying this. There is still quite a bit of nervousness around the markets.

Investors should watch the bounces and question what will be sustainable. 

We always need a villain – Inflation affects the market and conversely the sector with downslides has remained a dominant issue for investors.

I try to keep it simple and short … because there’s so much worry that people use any piece of good news as a chance to sell – it has become a process of developing ROI (return of investment).”

Reiterating, I believe there will be opportunity in cell and gene therapy equities but, the summer doldrums are still a roadblock. This period of volatility will likely last into the second half of the year.

However, the continuing state of volatility confirms fears that I have been expressing these daily and weekly posts.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.